NCT03562832Phase 2Completed

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Study sponsor: Allarity Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-04-01Actual
Enrollment · participants20Actual
Source updated2025-01-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview